These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9294123)

  • 41. Two vasopressin type 2 receptor gene mutations R143P and delta V278 in patients with nephrogenic diabetes insipidus impair ligand binding of the receptor.
    Tsukaguchi H; Matsubara H; Mori Y; Yoshimasa Y; Yoshimasa T; Nakao K; Inada M
    Biochem Biophys Res Commun; 1995 Jun; 211(3):967-77. PubMed ID: 7598729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
    Serradeil-Le Gal C; Raufaste D; Double-Cazanave E; Guillon G; Garcia C; Pascal M; Maffrand JP
    Kidney Int; 2000 Oct; 58(4):1613-22. PubMed ID: 11012895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes.
    Laugwitz KL; Ungerer M; Schöneberg T; Weig HJ; Kronsbein K; Moretti A; Hoffmann K; Seyfarth M; Schultz G; Schömig A
    Circulation; 1999 Feb; 99(7):925-33. PubMed ID: 10027817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Derivatives of somatic cell hybrids which carry the human gene locus for nephrogenic diabetes insipidus (NDI) express functional vasopressin renal V2-type receptors.
    Jans DA; van Oost BA; Ropers HH; Fahrenholz F
    J Biol Chem; 1990 Sep; 265(26):15379-82. PubMed ID: 2168411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
    Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
    Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site.
    Schülein R; Liebenhoff U; Müller H; Birnbaumer M; Rosenthal W
    Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):611-6. PubMed ID: 8573100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues.
    Schülein R; Zühlke K; Oksche A; Hermosilla R; Furkert J; Rosenthal W
    FEBS Lett; 2000 Jan; 466(1):101-6. PubMed ID: 10648821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiotensin II potentiates vasopressin-dependent cAMP accumulation in CHO transfected cells. Mechanisms of cross-talk between AT1A and V2 receptors.
    Klingler C; Ancellin N; Barrault MB; Morel A; Buhler JM; Elalouf JM; Clauser E; Lugnier C; Corman B
    Cell Signal; 1998 Jan; 10(1):65-74. PubMed ID: 9502119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vasopressin receptor-mediated endocytosis in cells transfected with V1-type vasopressin receptors.
    Lutz W; Sanders M; Salisbury J; Lolait S; O'Carroll AM; Kumar R
    Kidney Int; 1993 Apr; 43(4):845-52. PubMed ID: 8479120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calmodulin interacts with the V2 vasopressin receptor: elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium.
    Nickols HH; Shah VN; Chazin WJ; Limbird LE
    J Biol Chem; 2004 Nov; 279(45):46969-80. PubMed ID: 15319442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological lineage analysis revealed the binding affinity of broad-spectrum substance P antagonists to receptors for gonadotropin-releasing peptide.
    Arai K; Kashiwazaki A; Fujiwara Y; Tsuchiya H; Sakai N; Shibata K; Koshimizu TA
    Eur J Pharmacol; 2015 Feb; 749():98-106. PubMed ID: 25592317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
    Mouillac B; Mendre C
    Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
    Tan CM; Nickols HH; Limbird LE
    J Biol Chem; 2003 Sep; 278(37):35678-86. PubMed ID: 12824183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.
    Terrillon S; Durroux T; Mouillac B; Breit A; Ayoub MA; Taulan M; Jockers R; Barberis C; Bouvier M
    Mol Endocrinol; 2003 Apr; 17(4):677-91. PubMed ID: 12554793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
    J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maturation of receptor proteins in eukaryotic expression systems.
    Sadeghi HM; Innamorati G; Birnbaumer M
    J Recept Signal Transduct Res; 1997; 17(1-3):433-45. PubMed ID: 9029506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and characterization of a mouse cell line expressing the human V2 vasopressin receptor gene.
    Birnbaumer M; Hinrichs V; Themmen AP
    Mol Endocrinol; 1990 Feb; 4(2):245-54. PubMed ID: 2139494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors In vivo by ultrasound-guided injection or transcoronary delivery.
    Weig HJ; Laugwitz KL; Moretti A; Kronsbein K; Städele C; Brüning S; Seyfarth M; Brill T; Schömig A; Ungerer M
    Circulation; 2000 Apr; 101(13):1578-85. PubMed ID: 10747352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polarized cell surface expression of the green fluorescent protein-tagged vasopressin V2 receptor in Madin Darby canine kidney cells.
    Schülein R; Lorenz D; Oksche A; Wiesner B; Hermosilla R; Ebert J; Rosenthal W
    FEBS Lett; 1998 Dec; 441(2):170-6. PubMed ID: 9883878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase.
    Rosenthal W; Antaramian A; Gilbert S; Birnbaumer M
    J Biol Chem; 1993 Jun; 268(18):13030-3. PubMed ID: 8514744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.